In the intent-to-treat cohort (n = 19), with a median follow-up of at least 1 year, the median OS had not yet been reached with avasopasem manganese/SBRT (n = 11) compared with 40.4 weeks in the SBRT/placebo arm (n = 8; HR, 0.30; P = .046). Read more . . .
The addition of avasopasem manganese (GC4419) to stereotactic body radiation therapy (SBRT) led to a significant improvement in overall survival (OS) and favorable progression-free survival (PFS) versus SBRT plus placebo in patients with locally advanced pancreatic cancer, according to interim data from a phase 1/2 trial (NCT03340974) that were presented virtually during the 2020 ASTRO Annual Meeting.